Company: PFSA
Filing Date: 2025-07-18
Form Type: 8-K
Source: 0001213900-25-065686
Chunk: 2

Company: Profusa, Inc.
Filing Date: 2025-07-18
Form: 8-K
Item: Item 2.03
Chunk 2
---
 Some factors that could cause actual results to differ include:

  the benefits of the Business Combination;  

  the combined company’s financial performance following the Business Combination;  

  the ability to maintain the listing of our securities on Nasdaq following the Business Combination;  

  changes in Profusa’s strategy, future operations, financial position, estimated revenues and losses,  
  projected costs, prospects and plans;                                                                 
 ────────────────────────────────────────────────────────────────────────────────────────────────────────

  Profusa’s strategic advantages and the impact those advantages will have on future financial and  

  expansion plans and opportunities;  

  Profusa’s ability to grow its business in a cost-effective manner;  

  the implementation, market acceptance and success of Profusa’s business model;  

  developments and projections relating to Profusa’s competitors and industry;  

  Profusa’s approach and goals with respect to technology;  

  Profusa’s expectations regarding its ability to obtain and maintain intellectual property protection  

  political and economic instability, including the effects of Russia’s invasion of Ukraine and the  

  changes in applicable laws or regulations;  
 ──────────────────────────────────────────────

  the outcome of any known and unknown litigation and regulatory proceedings; and  

  other factors, including those set forth in the section of the Proxy Statement entitled “ Risk Factors”  

Business

The information set forth
in the section of the Proxy Statement entitled “ Profusa’s Business” beginning on page 233 is incorporated herein by
reference.

Risk Factors

The information
set forth in the section of the Proxy Statement entitled “ Risk Factors” beginning on page 27 is incorporated herein by reference.

Selected Consolidated Historical Financial
and Other Information

The information set
forth in the section of the Proxy Statement entitled “ Selected Historical Financial and Operating Data of Profusa” beginning
on page 22 is incorporated herein by reference.

Management’s Discussion and Analysis
of Financial Condition and Results of Operations

The following discussion
and analysis of the Company’s financial condition and results of operations should be read in conjunction with the unaudited condensed
consolidated financial statements and the notes thereto contained elsewhere in this Report. Certain information contained in the discussion
and analysis set forth below includes forward-looking statements that involve risks and uncertainties.

Business Overview

We are a clinical-stage digital
health and medical technology company focused on developing biosensing solutions to improve health outcomes for patients in a variety
of different diseases and conditions. Our first product is Lumee Oxygen, which enables physicians to